


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14Bring completed form to:
File Information Unit
Crystal Plaza Three, Room D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

In re Application of _____

Application Number

Filed

09/316935

5/22/99

Paper No. #23

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. 2003/0022860, page _____, line _____

United States Patent Number _____, column _____, line _____ or

WIPO Pub. No. _____, page _____, line _____

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public (see 37 CFR 1.14(c) if applicant) but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

Ricky Garcia
Signature

RICKY GARCIA
Typed or printed name

Registration Number, if applicable

703 413 0600

Telephone Number

Date

FOR PTO USE ONLY

Approved by: [Signature]

(initials)

Unit: File Information Unit

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US 20030022860A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0022860 A1**
Melief et al. (43) **Pub. Date: Jan. 30, 2003**(54) **CD40 BINDING MOLECULES AND CTL
PEPTIDES FOR TREATING TUMORS**(60) Provisional application No. 60/086,625, filed on May
23, 1998.(76) Inventors: **Cornelis J.M. Melief, Haarlem (NL);
Stephen P. Schoenberger, Encinitas,
CA (US); Rlenk Offringa, SJ Leiden
(NL); Rene Toes, HN Leiden (NL)****Publication Classification**(51) **Int. Cl.⁷** **A61K 48/00; A61K 39/395**
(52) **U.S. Cl.** **514/44; 424/141.1; 424/144.1;**
514/15

Correspondence Address:

TANOX, INC.**10301 STELLA LINK****HOUSTON, TX 77025 (US)**

(57)

ABSTRACT

Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab'), and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.

(21) Appl. No.: **10/227,789**(22) Filed: **Aug. 26, 2002****Related U.S. Application Data**(63) Continuation of application No. 09/316,935, filed on
May 22, 1999, now abandoned.